A changed hormone concentration does not automatically identify the receptor alteration responsible for it. A small human methamphetamine-abstinence study found higher plasma prolactin while its pituitary dopamine-receptor comparison was null. Preserving both findings makes the study more informative than a general claim of endocrine disruption.
What was measured during abstinence?
Zorick and colleagues studied 31 methamphetamine-dependent volunteers and 23 comparison participants. Blood was collected at 2:30 PM, including day 2 of supervised abstinence. Plasma prolactin averaged 11.3 ± 4.2 versus 8.1 ± 4.4 ng/mL (mean ± SD). A follow-up subset comprised 14 abstinent and 17 comparison participants around day 30. Daily urine testing supported abstinence. Zorick et al., 2011.
The study found no group difference in ACTH or cortisol and no significant group-by-time prolactin interaction. Pituitary D2-receptor availability, assessed with [18F]fallypride PET in 14 methamphetamine and 11 comparison participants, also did not differ significantly. Small samples and one afternoon sampling time limited sensitivity and assessment of daily hormonal variation. Clinical significance remained uncertain. Results and limitations.
Why does the PET null finding belong beside the prolactin result?
The two measurements address different levels of the proposed explanation. Blood establishes a circulating hormone concentration. PET binding estimates a receptor-availability measure in a specified anatomical structure. A positive group comparison in the first does not create a positive comparison in the second.
The null result does not prove every aspect of dopamine signaling was normal. It narrows what the experiment demonstrated. Receptor availability, dopamine release, synthesis and downstream signaling are different candidate processes; an unmeasured process should not be described as an observed explanation.
Why not interpret every participant as having a clinical hormone disorder?
A higher group mean relative to a comparison sample is not an individual diagnostic classification. Clinical interpretation would require the person’s own value, the relevant laboratory context and other clinical information. Converting the average difference into a diagnosis for all 31 participants would add a claim the group comparison does not establish.
The same caution applies to a single patient in a later case. An elevated prolactin result is not a specific methamphetamine test, an exposure clock or proof of a particular receptor lesion. Competing explanations require separate evaluation.
What does the follow-up actually show?
The follow-up subset is smaller than the entry sample. Describing the study as a complete month-long trajectory for all participants would erase that denominator change. A group effect at follow-up also differs from evidence that every individual increased, remained high or recovered.
A null interaction further limits the claim of different change over time. It should not be recast as proof of recovery or as proof that no person changed. The measured time points and the statistical comparison answer narrower questions.
What is the useful interpretation?
This historical observational study identifies a hormone finding worth explaining and tests one possible receptor-level correlate without confirming it. Its ACTH, cortisol and PET null results help define the biological specificity of the observation.
It does not provide a current diagnostic threshold, establish a treatment or infer impairment during an earlier event. A clear report states the hormone, specimen, units, sampling time and analyzed subgroup before advancing a mechanistic explanation.
Source
Zorick T, Mandelkern MA, Lee B, et al. Elevated plasma prolactin in abstinent methamphetamine-dependent subjects. The American Journal of Drug and Alcohol Abuse. 2011;37:62–67. doi:10.3109/00952990.2010.538945.